SpectrumX announces lab data showing its Spectricept™ product neutralises C. difficile spores within minutes
Lab tests shows that Spectricept™ neutralises a variety of common pathogens, including the spores of C. difficile, which are commonly found in hospitals and health care facilities and are a cause of hospital-acquired infection. Patent-pending formula benefiting from the sporicidal qualities of hypochlorous acid (HOCl) is pH neutral and skin-safe, with a ‘kill time’ of […]
SpectrumX reaches partnership agreement on human volunteer study for ground-breaking respiratory infection drug candidate SPX-001
Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001 Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001 Partner and SpectrumX will align on detailed clinical trial protocol to […]
SpectrumX announces significant updates at Knutsford production facility
Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space Knutsford, United Kingdom– SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the […]
SpectrumX expands R&D division with appointment of microbiology team
In-house Microbiology laboratory commissioned to accelerate product range development and enhance differentiation
SpectrumX confirms scientific advice meeting with MHRA, proposed timeline for human clinical trials for ground-breaking medicine SPX-001
The Company identifies critical milestones required to commence clinical trial programme London, United Kingdom, 8 August 2022: SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce that is has a date for a scientific advice meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to discuss its human clinical trial programme. SpectrumX […]
SpectrumX confirms scientific advice meeting with MHRA, proposed timeline for human clinical trials for ground-breaking medicine SPX-001
The Company identifies critical milestones required to commence clinical trial programme
SpectrumX Strengthens Senior Leadership
Pharma and healthcare experts Dr Donna Lockhart and Greg Whelan join with newly created roles of Head of Medicines and Group Sales Director as business progresses
